Business Standard
Thursday, May 17, 2012
Sponsored by  
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||||Economy & Policy||||| 
 Section Home | News Now | Today's Paper | Features & Analysis | Politics & Public Affairs | Q&A | Columnists | BS Says
Home > Economy & Policy Live Markets | Commodities
 

A finger in every pie
Chitra Unnithan / Aug 04, 2010, 20:24 IST

Janmejay Vyas has in a short period of time diversified into multiple areas.

Dishman Pharmaceuticals and Chemicals Limited (DPCL), the company that Jay R Vyas heads, was incorporated in 1983 as a research-oriented organisation. It was originally incorporated as Dishman Pharmaceuticals and Chemicals Private Limited, a private limited company with J R Vyas as a shareholder and director.

BSE | NSE
Price  
Dishman Pharma
The company was dormant until 1989 when Vyas — who holds a bachelor’s degree in chemistry from St. Xavier’s College, Ahmedabad and a bachelor’s degree in Pharma & Fine Chemical Technology from the UDCT, Mumbai — activated it and was appointed its managing director.

Ahmedabad-based Dishman Pharma, now a Rs 1,000 crore company, operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quaternary compounds and specialty chemicals. It is involved in the manufacture of active pharmaceutical ingredients (APIs), intermediates, quaternary compounds and fine chemicals.

Dishman Pharma is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients.

Dishman has established two wholly-owned subsidiaries — Dishman Europe Ltd. and Dishman Cyprus Ltd. Listed on the Bombay Stock Exchange (BSE), the company has five business units. Dishman Specialty Chemicals in India and China makes phase transfer catalysts, supplying high-quality intermediates, fine chemicals, and products for the pharmaceutical, cosmetics and related industries. Carbogen Amcis in Switzerland, with operations in UK and India, is a process R & D facility that supplies APIs to support clinical trial requirements.

Dishman Corporate Research and Manufacturing Services (CRAMS) in India and China provides a high-value, cost-competitive contract services facility. Dishman Vitamins & Chemicals in Netherlands and India offers Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and lanolin-related products for the pharmaceuticals, cosmetics and related markets.

Dishman Disinfectants in India, Australiasia and Saudi Arabia on the other hand is a next-generation innovative antiseptic and disinfectant formulations unit.

“I saw the need for a company that could provide high-quality, high-value products and services and be a good and reliable partner to pharmaceutical companies worldwide,” says Vyas.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets turn volatile in late noon trades
- FDI, portfolio flows remain strong, India assures Fitch
- Coriander rises 2% on firm spot demand
- Maize up on global cues
- Silver futures rebound on global cues
  Read Business news in 
- Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol.
- The Best Seller is Also the No. 1 in Mileage. Click here
- One Partnership Endless Possibilities. Click here to know more
- A Brand New Server at a Price That Fits Your Budget. Click here
- Watch The Film Here. Click here to know more..
- 1 billion in saving for Unilever without any tangles.
- Learn How One City is Running on FOOD SCRAPS.
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
Where do you see Nifty at the end of the year?
  4,500
  5,000
  5,500
Submit
Most Popular
Read
E-Mailed
Commented
   
- RBI digs deep but rupee sinks further
- FM signals tough measures for hard times, austerity coming
- RBI seeks forex conversion data
- Most of our customers are upgrading from Royal Enfield: Anoop Prakash
- MCA lodges police complaint against SRK, bans him for life
 
 More  
New Ipad Application
 Business Standard's all new IPad  App
 Click here to download for free
  Hot Searches  
 
Creamy layer |  Air India |  GAAR |  DRDO  |  Black Widow |  Satyamev Jayate |  Akshaya Tritiya |  Aamir Khan |  IPL |  IVRCL |  Ertiga |  Sarfaesi Act |  Vodafone |  Imagine TV |  Transfer pricing |  Rupee |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  Budget 2012 |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us